Content provided in partnership with
Technology Industry
Industry: Email Alert RSS FeedTranzyme Inc
BT Catalyst, July-August, 2002
Tranzyme Inc. of Birmingham, Ala., and Targacept Inc. of Winston-Salem are partnering to develop a novel bioassay for drug discovery in the area of central nervous system diseases. Under the terms of the agreement, Tranzyme will employ the combination of its proprietary technologies for gene transfer and assay development to develop a novel cell-based assay expressing nicotinic acetylcholine receptors provided by Targacept.
- Most Popular Articles in Technology
- An overview of continuous data protection
- Why all those current ratings?
- Many countries now have a mobile penetration rate above 100%, report says
- The Tata Group's big telecom gamble: VSNL's recent acquisition of Tyco ...
- MEASURING BANK BRANCH EFFICIENCY USING DATA ENVELOPMENT ANALYSIS: MANAGERIAL ...
- More »
These receptors are implicated in a variety of neurodegenerative diseases.
COPYRIGHT 2002 North Carolina Biotechnology Center
COPYRIGHT 2008 Gale, Cengage Learning
Find Research Guides for:
Find Featured Titles for: News
Most Popular Articles in Technology
- An overview of continuous data protection
- Why all those current ratings?
- Many countries now have a mobile penetration rate above 100%, report says
- The Tata Group's big telecom gamble: VSNL's recent acquisition of Tyco ...
- MEASURING BANK BRANCH EFFICIENCY USING DATA ENVELOPMENT ANALYSIS: MANAGERIAL ...
- More »